Myriad Genetics, Inc.
MYGN
Market Cap$453.51M
Close$
$-8.81
281.3% downside
Current Fair Value
281.3% downsideOvervalued by 281.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $453.51 Million |
|---|---|
| Enterprise Value | $500.91 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.18 |
| Beta | 1.85 |
| Outstanding Shares | 90,900,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.86 |
|---|---|
| PEG | 6.03 |
| Price to Sales | 0.54 |
| Price to Book Ratio | 0.61 |
| Enterprise Value to Revenue | 0.61 |
| Enterprise Value to EBIT | -4.52 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Myriad Genetics, Inc.
2,600 employees
CEO: R. Bryan Riggsbee Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accura...